GLP-1
LGC, Biosearch Technologies proudly introduces RapiDxFire™ Thermostable RT, a truly thermostable reverse transcriptase designed specifically to meet the needs of diagnostic kit developers.
Novo Nordisk announced the results from its SUSTAIN 9 Phase IIIb trial. The trial compared Novo’s Ozempic (semaglutide) with an SGLT-2 inhibitor or placebo in adults with type 2 diabetes.
In what is likely a preemptive move to avoid government action on insulin prices, Eli Lilly announced it will start selling an “authorized generic” version of Humalog 100 at about 50 percent off the list prices.
FINCH 2 Phase 3 trial with filgotinib in rheumatoid arthritis (RA) met all primary and secondary endpoints, with consistent tolerability
Adocia announced that four abstracts featuring its BioChaperone® technology have been accepted for presentation at the 12th International Conference on Advanced Technologies & Treatments for Diabetes being held February 20-23, 2019 in Berlin, Germany.
Mechelen, Belgium, and Hamburg, Germany; 7 February 2019, 7.30 CET - Evotec AG, and Galapagos NV announced a global collaboration focused on a novel target for fibrosis and other indications.
Many of the big biopharma companies reported fourth-quarter and year-end earnings this week. If there’s a theme among them, it seems lower earnings per share are forecast for the year.
Robert Jacks, co-founder and former chief financial officer of Symbiomix Therapeutics, has taken over the reins of Cambridge, Mass.-based Indalo Therapeutics and will help guide the company in the development of therapies for patients suffering from serious fibrotic diseases such as NASH and idiopathic pulmonary fibrosis (IPF).
Adocia confirmed its financial calendar for 2019 with a change in date of the annual shareholder’s meeting.
Days after acquiring Loxo Oncology, Eli Lilly Chief Executive Officer David Ricks outlined projections for the new year and said that he, and other executive leaders, feel confident about the position that the company now finds itself in during a fireside chat at the J.P. Morgan Healthcare Conference.
PRESS RELEASES